tetano
Editor, Senior Moderator
Vaccine
. 2021 May 12;S0264-410X(21)00551-X.
doi: 10.1016/j.vaccine.2021.05.001. Online ahead of print.
Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ? 65 years
Tae Hyong Kim[SUP] 1 [/SUP], Jung-Hyun Choi[SUP] 2 [/SUP], Sun Hee Park[SUP] 3 [/SUP], Jin-Hong Yoo[SUP] 4 [/SUP], Dong Gun Lee[SUP] 5 [/SUP], Su-Mi Choi[SUP] 6 [/SUP], Yang Ree Kim[SUP] 7 [/SUP], Mi Suk Lee[SUP] 8 [/SUP], Eun Ju Choo[SUP] 9 [/SUP], Hee Jung Choi[SUP] 10 [/SUP]
Affiliations
Abstract
Background: Seasonal Influenza is still considered associated with seasonal morbidity and hospitalization in the elderly population. The World Health Organization (WHO) recommended seasonal quadrivalent influenza vaccine (QIV) to reduce burden of two currently circulating influenza B lineages. Until 2019 Korean National Immunization Program (NIP) recommended trivalent influenza vaccine (TIV) after ongoing debates on cost effectiveness of QIV for elderly population. Although influenza vaccine only showed modest effect on reducing influenza in elderly, this study aimed to evaluate the immunogenicity and safety of inactivated QIV in healthy participants ? 65 years of age.
Methods: A total of 274 healthy participants aged ? 65 years received a QIV. Seroconversion-based vaccine efficacy of 4 strains of seasonal influenza was assessed 21 days after vaccination and adverse events were monitored until 180 days after vaccination.
Results: The percentages of participants seroconverted after vaccination on HI antibody against each strain were 36.5% (99/271) to A/H1N1, 47.6% (129/271) to A/H3N2, 40.6% (110/271) to B Yamagata, and 49.1% (133/271) to B Victoria. The percentages of participants seroprotected after vaccination on HI antibody against each strain were 81.2% (220/271) to A/H1N1, 98.5% (267/271) to A/H3N2, 95.2% (258/271) to B Yamagata, and 93.7% (254/271) to B Victoria. There was no serious adverse event (SAE) related with the study vaccine.
Conclusion: The quadrivalent split influenza vaccine is expected to offer seroprotection against influenza A and both influenza B lineages even in the elderly population.
Keywords: Immunogenicity; Quadrivalent Influenza Vaccine; Safety.
. 2021 May 12;S0264-410X(21)00551-X.
doi: 10.1016/j.vaccine.2021.05.001. Online ahead of print.
Safety and immunogenicity of a seasonal quadrivalent influenza vaccine (GC3110A) in healthy participants aged ? 65 years
Tae Hyong Kim[SUP] 1 [/SUP], Jung-Hyun Choi[SUP] 2 [/SUP], Sun Hee Park[SUP] 3 [/SUP], Jin-Hong Yoo[SUP] 4 [/SUP], Dong Gun Lee[SUP] 5 [/SUP], Su-Mi Choi[SUP] 6 [/SUP], Yang Ree Kim[SUP] 7 [/SUP], Mi Suk Lee[SUP] 8 [/SUP], Eun Ju Choo[SUP] 9 [/SUP], Hee Jung Choi[SUP] 10 [/SUP]
Affiliations
- PMID: 33992436
- DOI: 10.1016/j.vaccine.2021.05.001
Abstract
Background: Seasonal Influenza is still considered associated with seasonal morbidity and hospitalization in the elderly population. The World Health Organization (WHO) recommended seasonal quadrivalent influenza vaccine (QIV) to reduce burden of two currently circulating influenza B lineages. Until 2019 Korean National Immunization Program (NIP) recommended trivalent influenza vaccine (TIV) after ongoing debates on cost effectiveness of QIV for elderly population. Although influenza vaccine only showed modest effect on reducing influenza in elderly, this study aimed to evaluate the immunogenicity and safety of inactivated QIV in healthy participants ? 65 years of age.
Methods: A total of 274 healthy participants aged ? 65 years received a QIV. Seroconversion-based vaccine efficacy of 4 strains of seasonal influenza was assessed 21 days after vaccination and adverse events were monitored until 180 days after vaccination.
Results: The percentages of participants seroconverted after vaccination on HI antibody against each strain were 36.5% (99/271) to A/H1N1, 47.6% (129/271) to A/H3N2, 40.6% (110/271) to B Yamagata, and 49.1% (133/271) to B Victoria. The percentages of participants seroprotected after vaccination on HI antibody against each strain were 81.2% (220/271) to A/H1N1, 98.5% (267/271) to A/H3N2, 95.2% (258/271) to B Yamagata, and 93.7% (254/271) to B Victoria. There was no serious adverse event (SAE) related with the study vaccine.
Conclusion: The quadrivalent split influenza vaccine is expected to offer seroprotection against influenza A and both influenza B lineages even in the elderly population.
Keywords: Immunogenicity; Quadrivalent Influenza Vaccine; Safety.